Efficacy and Safety Study of Tafenoquine (TQ) Co-administered with Dihydroartemisin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria in Indonesian Soldiers
In 2016 ALERTAsia signed agreement with GlaxoSmithKline to assist in conducting study on efficacy and safety of Tafenoquine co-administered with Dihydroartemisinin-piperaquine (DHA-PQP) for the radical cure of Plasmodium Vivax Malaria on Indonesian Soldiers. The implementing partners are TNI-AD (Indonesian Army), KemenRistekDikti/Eijkman Institute for Molecular Biology, Faculty of Medicine of Universitas Indonesia, and Oxford University/Eijkman-Oxford Clinical Research Unit. In April 2018 the study has reached its third phase, i.e. enrollment of participants at Mechanical Batalyon 512/QY, Malang, East Java.